Gene Expression Assay for Acute Cellular Rejection Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing acute cellular rejection (ACR) in kidney allografts are cumbersome, expensive, and often too late to prevent rejection, relying on invasive biopsies and non-predictive serum markers like serum creatinine and urine protein levels.
Innovation Solution
A blood-based assay measuring the expression levels of a preselected gene signature set, including genes such as ANXA5, TSC22D1, AP1M1, CLK1, EFTUD2, SENP6, and SENP7, using next-generation sequencing technologies to calculate a probability score for acute cellular rejection risk, allowing for early intervention with immunosuppressive drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biopsy specimens are used to diagnose acute cellular rejection, then diagnostic accuracy is improved, but patient invasiveness and procedure complexity increase
Solution Approach 1:
The patent uses gene expression profiles from peripheral blood mononuclear cells as an intermediary marker to detect acute cellular rejection. Instead of directly examining the graft tissue through biopsy, the method measures mRNA expression levels of specific genes (such as CXCL9, CXCL10, CCL5) in blood cells, which serve as mediators reflecting the rejection state of the allograft. This intermediary approach maintains diagnostic accuracy while eliminating the invasive nature of biopsy procedures
Solution Approach 2:
The patent replaces the mechanical biopsy procedure with a molecular biology-based assay. Instead of physically extracting tissue samples through surgical intervention, the method uses RNA extraction and quantitative real-time PCR to detect gene expression patterns in peripheral blood. This substitution transforms a mechanical invasive procedure into a non-invasive molecular detection system that achieves comparable or superior diagnostic precision
2Ease of operation
If serum creatinine or urine protein levels are measured, then ease of operation is improved, but predictive accuracy of rejection deteriorates
Solution Approach 1:
The patent changes the measured parameter from conventional clinical chemistry markers (serum creatinine, urine protein) to molecular biology parameters (gene expression levels). By measuring mRNA expression levels of rejection-specific genes in peripheral blood mononuclear cells using quantitative real-time PCR, the method achieves both ease of operation comparable to standard blood tests and dramatically improved predictive accuracy for acute cellular rejection
Solution Approach 2:
The patent creates a molecular copy or surrogate marker system where gene expression profiles in peripheral blood cells serve as a copy of the rejection state occurring in the allograft. Instead of directly measuring rejection in the kidney tissue, the method detects equivalent molecular signatures in easily accessible blood samples, maintaining operational simplicity while achieving accurate prediction
3Loss of time
If early rejection is detected using gene expression analysis, then loss of time for intervention is reduced, but device complexity and measurement complexity increase
Solution Approach 1:
The patent segments the complex task of rejection detection by focusing on a specific subset of genes with known roles in rejection pathways (such as CXCL9, CXCL10, CCL5). Instead of analyzing the entire transcriptome or using complex multi-parameter assays, the method divides the problem into measuring expression levels of a defined panel of rejection-specific genes in peripheral blood mononuclear cells, simplifying the measurement process while enabling early detection
Solution Approach 2:
The patent performs preliminary identification and validation of rejection-specific gene signatures before clinical application. By pre-selecting genes that are specifically upregulated during acute cellular rejection and establishing their diagnostic utility in advance, the method enables rapid point-of-care testing without requiring complex real-time analysis systems. The preliminary work of gene selection and validation simplifies the actual clinical measurement process
Data Source
AI summary
Disclosed herein are methods for diagnosing acute cellular rejection (ACR) of an allograft by analysis of predictive gene sets and kits for practicing these methods.